4% Articadent DENTAL with adrenaline (epinephrine) 1:100,000 articaine hydrochloride and adrenaline (epinephrine) 2.2 mL injection cartridge Australia - English - Department of Health (Therapeutic Goods Administration)

4% articadent dental with adrenaline (epinephrine) 1:100,000 articaine hydrochloride and adrenaline (epinephrine) 2.2 ml injection cartridge

dentsply sirona pty ltd - articaine hydrochloride, quantity: 40 mg/ml; adrenaline (epinephrine) acid tartrate, quantity: 18.2 microgram/ml (equivalent: adrenaline (epinephrine), qty 10 microgram/ml) - injection, solution - excipient ingredients: sodium chloride; sodium metabisulfite; sodium hydroxide; hydrochloric acid; water for injections - 4 percent articadent dental with adrenaline 1:100,000 is indicated for local or regional anaesthesia for both simple and complex dental procedures in adults, adolescents and children 4 years of age and older. 4 percent articadent dental with adrenaline 1:100,000 is indicated only for dental procedures.

AZADINE azacitidine 100 mg powder for injection vial Australia - English - Department of Health (Therapeutic Goods Administration)

azadine azacitidine 100 mg powder for injection vial

dr reddys laboratories australia pty ltd - azacitidine, quantity: 100 mg - injection, powder for - excipient ingredients: mannitol - azadine is indicated for the treatment of patients with intermediate-2 and high-risk myelodysplastic syndromes (mds) according to the international prognostic scoring system (ipss), chronic myelomonocytic leukemia (cmmol (10-29 percent marrow blasts without myeloproliferative disorder)), acute myeloid leukemia (aml) with 20-30 percent blasts and multi-lineage dysplasia, according to world health organisation classification (who), in whom allogenic stem cell transplantation is not indicated.

0.9% SODIUM CHLORIDE INTRAVENOUS INFUSION BP 0.9% sodium chloride 50 mL intravenous infusion Australia - English - Department of Health (Therapeutic Goods Administration)

0.9% sodium chloride intravenous infusion bp 0.9% sodium chloride 50 ml intravenous infusion

b braun australia pty ltd - sodium chloride, quantity: 0.45 g - injection, solution - excipient ingredients: water for injections - the solutions are indicated for intravenous fluid therapy designed to correct deficiencies in hydration, electrolyte and energy levels. the solutions may also be used as solvents for intravenously administered drugs where compatibility has been established. 0.9% sodium chloride injection may also be used for irrigation of wounds and moistening of wound dressings. compound sodium lactate solution is particularly suitable for the replacement of extracellular fluid loss where isotonic dehydration is evident and in burn therapy.

VIDAZA azacitidine 100mg powder for injection Australia - English - Department of Health (Therapeutic Goods Administration)

vidaza azacitidine 100mg powder for injection

celgene pty ltd - azacitidine, quantity: 100 mg - injection, powder for - excipient ingredients: mannitol - a)intermediate-2 and high-risk myelodysplastic syndromes (mds) according to the international prognostic scoring system (ipss), b)chronic myelomonocytic leukemia (cmmol 10%-29% marrow blasts without myeloproliferative disorder)), c) acute myeloid leukemia (aml) with 20-30% blasts and multi-lineage dysplasia, according to world health organisation classification (who). in whom allogenic stem cell transplantation is not indicated.

FOSCAVIR foscarnet sodium 6g/250mL injection bottle Australia - English - Department of Health (Therapeutic Goods Administration)

foscavir foscarnet sodium 6g/250ml injection bottle

link medical products pty ltd t/a link pharmaceuticals - foscarnet sodium, quantity: 24 mg/ml - injection, solution - excipient ingredients: water for injections; hydrochloric acid - treatment of cytomegalovirus (cmv) retinitis in patients with the acquired immunodeficiency syndrome (aids). indications as at 11 november 1994: for treatment of cytomegalovirus (cmv) retinitis in patients with acquired immunodeficiency syndrome (aids); and treatment of aciclovir resistant herpes simplex virus (hsv) infections (defined by clinical trial or in-vitro resistance) in immunocompromised patients with human immunodeficiency virus (hiv) infection. note: the indication for treatment of aciclovir resistant hsv infections in immunocompromised patients with hiv infections is based primarily on the results of one open label comparative study. this was of patients with hiv infections and herpetic lesions unresponsive to aciclovir administered intravenously for 10 days or more and in-vitro documented resistance to aciclovir. eight patients were randomised to foscarnet (40mg/kg iv given eight hourly) and 6 were randomised to vidarabine 15mg/kg iv daily. the results showed a significant difference in favour o

AZACITIDINE-TEVA azacitidine 100 mg powder for injection vial Australia - English - Department of Health (Therapeutic Goods Administration)

azacitidine-teva azacitidine 100 mg powder for injection vial

teva pharma australia pty ltd - azacitidine, quantity: 100 mg - injection, powder for - excipient ingredients: monobasic sodium phosphate monohydrate; dibasic sodium phosphate dihydrate; sucrose - azacitidine-teva is indicated for the treatment of patients with: intermediate-2 and high-risk myelodysplastic syndromes (mds) according to the international prognostic scoring system (ipss), chronic myelomonocytic leukemia [cmmol (10 percent-29 percent marrow blasts without myeloproliferative disorder)], acute myeloid leukemia (aml) with 20-30 percent blasts and multi-lineage dysplasia, according to world health organisation classification (who), in whom allogenic stem cell transplantation is not indicated

Thermometer, infrared, skin Australia - English - Department of Health (Therapeutic Goods Administration)

thermometer, infrared, skin

drewson international pty ltd t/a briggate medical company - 17888 - thermometer, infrared, skin - hand-held battery powered device that is intended to be used for the monitoring of body temperature of people of all ages. it measures the infrared energy emitted from the skin surface of the forehead so there is no need for contact with the skin. it is accurate and simple to operate and can be used in the home or clinic.

XOROX aciclovir 30 mg/g eye ointment tube Australia - English - Department of Health (Therapeutic Goods Administration)

xorox aciclovir 30 mg/g eye ointment tube

agepha pharma pty ltd - aciclovir, quantity: 0.135 g - eye ointment - excipient ingredients: white soft paraffin - aciclovir is indicated for the treatment of herpes simplex keratitis.

Hospital Plus Surface Spray Disinfectant Australia - English - Department of Health (Therapeutic Goods Administration)

hospital plus surface spray disinfectant

international consolidated business group pty ltd - 9950 - disinfectant, hospital grade - other therapeutic

ANDROFEME 1 testosterone 1% w/v (10 mg/mL) cream tube Australia - English - Department of Health (Therapeutic Goods Administration)

androfeme 1 testosterone 1% w/v (10 mg/ml) cream tube

lawley pharmaceuticals pty ltd - testosterone, quantity: 10 mg/ml - cream - excipient ingredients: almond oil; butylated hydroxytoluene; carbomer 940; cetomacrogol 1000; cetostearyl alcohol; citric acid; dl-alpha-tocopheryl acetate; trolamine; purified water; phenoxyethanol; propyl hydroxybenzoate; ethyl hydroxybenzoate; isobutyl hydroxybenzoate; butyl hydroxybenzoate; methyl hydroxybenzoate - androfeme 1 is indicated for the treatment of hypoactive sexual desire dysfunction (hsdd) in postmenopausal women. therapeutic intervention with androfeme 1 should only be initiated in women following failure of appropriate education and correction of modifiable biopsychosocial factors (which may include neuroendocrine imbalance, physical ill health or disease, interpersonal difficulties, psychological distress or specific cultural or religious beliefs), according to the international society for the study of women?s sexual health (isswsh) process of care (see figure 1).